TRCT
PTCT icon

Tower Research Capital (TRC)’s PTC Therapeutics PTCT Stock Holding History

Tower Research Capital (TRC)’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$266K Sell
3,255
-4,910
-60% -$355K 0.01% 1484
2026
Q1 		$556K Buy
8,165
+3,802
+87% +$269K 0.01% 837
2025
Q4 		$331K Buy
4,363
+1,663
+62% +$121K 0.01% 1089
2025
Q3 		$166K Sell
2,700
-4,609
-63% -$240K ﹤0.01% 1620
2025
Q2 		$357K Buy
7,309
+5,615
+331% +$267K 0.01% 1273
2025
Q1 		$86.3K Sell
1,694
-14,859
-90% -$741K ﹤0.01% 1850
2024
Q4 		$747K Buy
16,553
+16,110
+3,637% +$689K 0.01% 809
2024
Q3 		$16.4K Sell
443
-15,817
-97% -$530K ﹤0.01% 3361
2024
Q2 		$497K Buy
16,260
+15,435
+1,871% +$500K 0.01% 1349
2024
Q1 		$24K Sell
825
-5,823
-88% -$163K ﹤0.01% 2836
2023
Q4 		$183K Buy
6,648
+4,272
+180% +$97.7K ﹤0.01% 2176
2023
Q3 		$53.2K Sell
2,376
-7,983
-77% -$297K ﹤0.01% 2497
2023
Q2 		$421K Buy
10,359
+6,437
+164% +$315K 0.01% 1090
2023
Q1 		$190K Buy
3,922
+1,881
+92% +$86K 0.01% 1396
2022
Q4 		$78K Sell
2,041
-26,594
-93% -$1.11M ﹤0.01% 2026
2022
Q3 		$1.44M Buy
28,635
+6,635
+30% +$325K 0.02% 547
2022
Q2 		$882K Buy
22,000
+14,982
+213% +$525K 0.02% 779
2022
Q1 		$261K Sell
7,018
-3,824
-35% -$147K ﹤0.01% 1548
2021
Q4 		$432K Buy
10,842
+5,027
+86% +$192K 0.01% 1210
2021
Q3 		$217K Sell
5,815
-285
-5% -$11.7K 0.01% 1747
2021
Q2 		$258K Sell
6,100
-1,486
-20% -$63.7K 0.01% 1725
2021
Q1 		$359K Buy
7,586
+5,103
+206% +$303K 0.01% 1512
2020
Q4 		$152K Buy
2,483
+253
+11% +$14.9K ﹤0.01% 1966
2020
Q3 		$104K Sell
2,230
-4,939
-69% -$243K ﹤0.01% 3119
2020
Q2 		$364K Buy
+7,169
New +$352K 0.01% 1284
2020
Q1 		– Sell
-39
Closed -$2K – 3720
2019
Q4 		$2K Sell
39
-3,804
-99% -$162K ﹤0.01% 3094
2019
Q3 		$130K Buy
+3,843
New +$167K 0.01% 1198
2019
Q1 		– Sell
-2,106
Closed -$72K – 4180
2018
Q4 		$72K Buy
+2,106
New +$75.7K 0.01% 1111
2018
Q3 		– Sell
-442
Closed -$15K – 4155
2018
Q2 		$15K Sell
442
-6,914
-94% -$216K ﹤0.01% 2595
2018
Q1 		$199K Buy
7,356
+5,943
+421% +$151K 0.02% 882
2017
Q4 		$24K Buy
1,413
+859
+155% +$14.5K ﹤0.01% 1924
2017
Q3 		$11K Buy
+554
New +$10.8K ﹤0.01% 3039
2017
Q1 		– Sell
-5,510
Closed -$60K – 3737
2016
Q4 		$60K Buy
+5,510
New +$57.8K 0.01% 1305
2016
Q3 		– Sell
-900
Closed -$6K – 4266
2016
Q2 		$6K Buy
900
+700
+350% +$5.13K ﹤0.01% 3285
2016
Q1 		$1K Sell
200
-667
-77% -$11.6K ﹤0.01% 3750
2015
Q4 		$28K Buy
+867
New +$25.5K ﹤0.01% 953
2015
Q3 		– Sell
-1,387
Closed -$67K – 4612
2015
Q2 		$67K Sell
1,387
-449
-24% -$26.2K 0.01% 1142
2015
Q1 		$112K Buy
+1,836
New +$112K 0.01% 793
2014
Q3 		– Sell
-37
Closed -$1K – 4798
2014
Q2 		$1K Buy
+37
New +$792 ﹤0.01% 3736
2014
Q1 		– Sell
-400
Closed -$7K – 4823
2013
Q4 		$7K Sell
400
-537
-57% -$9.44K ﹤0.01% 3304
2013
Q3 		$20K Buy
+937
New +$16.3K ﹤0.01% 2682

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Tower Research Capital (TRC)'s PTCT Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its PTC Therapeutics (PTCT) stake by 60% in Q2 2026, selling an estimated $355K and leaving 3,255 shares worth $266K. The position accounts for 0.01% of the portfolio, ranked #1484.

Tower Research Capital (TRC) first reported a position in PTCT in Q3 2013 and has held it in 41 quarters since. The position peaked at $1.44M in Q3 2022. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Tower Research Capital (TRC) held 3,255 shares of PTC Therapeutics worth $266K as of Q2 2026.
  • Tower Research Capital (TRC) sold 4,910 PTC Therapeutics shares in Q2 2026, an estimated $355K.
  • PTC Therapeutics made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #1484 holding.
  • Tower Research Capital (TRC) first reported a position in PTC Therapeutics in Q3 2013 and has held it in 41 quarters since.
  • Tower Research Capital (TRC)'s PTC Therapeutics position peaked at $1.44M in Q3 2022.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.